Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
|
|
|
- Duane Day
- 6 years ago
- Views:
Transcription
1 Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney Institute Cleveland Clinic
2 Invasive Bladder Cancer Usually a lethal disease Cancer Statistics: US 70,530 cases in 2010 (~ 23,000 HG TCC) 14,680 deaths (majority from HG TCC) Incidence : Mortality for HG TCC 1.6 : 1 Jemal et al. CA Cancer J Clin 2010
3 Invasive Bladder Cancer Usually a lethal disease Cancer Statistics: US 70,530 cases in 2010 (~ 23,000 HG TCC) 14,680 deaths (majority from HG TCC) Incidence : Mortality for HG TCC 1.6 : 1 Jemal et al. CA Cancer J Clin 2010
4 Invasive Bladder Cancer Usually a lethal disease Cancer Statistics: US 70,530 cases in 2010 (~ 23,000 HG TCC) 14,680 deaths (majority from HG TCC) Incidence : Mortality for HG TCC 1.6 : 1 (Lung 1.4 : 1) Jemal et al. CA Cancer J Clin 2010
5 Cystectomy: Too Often Too Late! PT0-2 PT3-4 PN1-2 MSKCC, USA 52% 48% 22% USC, USA 51% 49% 23% Bern, SUI 48% 52% 24% Leissner et al., GER 52% 48% 28% Shariat et al., USA 57% 43% 23% Herr et al., USA 55% 45% 20%
6 Post-Cystectomy Survival Post-Cystectomy Survival 1.0 pt2, N0 0.5 pt3-4, N0 pn Years Stein et al. J Clin Oncol 2001
7 Radical Cystectomy: Optimizing Outcomes Timely cystectomy for T1, TaHG, CIS Quality of radical cystectomy Extended pelvic lymphadenectomy Peri-operative systemic therapy Improve morbidity and HRQOL
8 Perioperative Chemotherapy National Cancer Database (USA) Only 11.6% of eligible cystectomy patients received any form of perioperative chemotherapy 16.8% in 2003 Majority received adjuvant chemotherapy (10.4%) Few patients received neoadjuvant therapy (1.2%) David et al. J Urol 2007
9 Neoadjuvant MVAC Chemotherapy: SWOG 8710 All-cause mortality: 25% RRR 5-yr survival: 57% vs. 43% Bladder cancer-specific mortality: 40% RRR (P =.002) Benefit observed across all stages Grossman et al. N Engl J Med 2003
10 Neoadjuvant MVAC Chemotherapy: SWOG 8710 Dotan et al ASCO 2005
11 Optimal Therapy for Invasive Bladder Cancer Survival Local Rec Neoadjuvant Chemo, RC, > 10 LN 81% 9% RC, > 10 LN removed 66% 10% Neoadjuvant Chemo, RC, 10 LN 55% 23% RC, 10 LN removed 39% 44% No cystectomy 11% Dotan et al. ASCO 2005
12 Neoadjuvant CMV Chemotherapy: BA N = 976, , median FU 8 yrs, 58% RC Mortality: HR 0.8; 95% CI: ; P = yr survival: 36% vs. 30% Mets: HR 0.8; 95% CI: ; P =.001 Griffiths et al. J Clin Oncol 2011
13 Neoadjuvant Chemotherapy Meta-analysis: 6 RCT, 2116 pts Mortality: HR 0.9; 95% CI: ; P =.003 5% absolute survival benefit at 5 years Advanced Bladder Cancer Meta-Analysis Collab. et al. Lancet 2003; Eur Urol 2005
14 Why Not Adjuvant Instead of Neoadjuvant? Similar evidence exists for a survival benefit with adjuvant chemotherapy? Over-treatment: Many ct2 patients with have organconfined bladder cancer and are cured with cystectomy alone? Chemotherapy delays surgery and leads to increased complications? Patients are just as likely to receive 3-4 cycles of chemotherapy in the adjuvant setting as the neoadjuvant setting?
15 Survival Benefit with Adjuvant Chemotherapy? Meta-analysis: 4 RCT, 491 pts Insufficient power Mortality: 0.8; 95% CI: ; P =.002 Advanced Bladder Cancer Meta-Analysis Collaboration et al. Eur Urol 2005
16 Survival Benefit with Adjuvant Chemotherapy? 114 pts pt1-2, N0 and p53+ randomized to adjuvant MVACx3 vs. observation Only 67% pts randomized to adjuvant MVAC received 3 cycles Under-powered 50% recurrence rate in control arm, planned accrual 190 pts Stadler et al. J Clin Oncol 2011
17 Survival Benefit with Adjuvant Chemotherapy? 194 pts with pt2-4, N0-2 bladder cancer randomized to adjuvant GCx4 vs observation Powered to detect 20% improvement in OS at 2 years, planned accrual 610 pts Cognetti et al. Ann Oncol 2011
18 Many clinical T2 patients have organ-confined bladder cancer and are cured by cystectomy alone? Clinically localized Pathologically advanced Clinical T2 (67-82%) 49% pt3-4, 23% pn+ Clinical T3-4 (18-33%) 84% pt3-4, 26-60% pn+ Shariat et al. Eur Urol 2007
19 Many clinical T2 patients have organ-confined bladder cancer and are cured by cystectomy alone? Clinically localized Pathologically advanced Clinical T2 (67-82%) 49% pt3-4, 23% pn+ Clinical T3-4 (18-33%) 84% pt3-4, 26-60% pn+ pt2n0 bladder cancer 25-30% mortality at 5 yrs Are your patients satisfied with a 1 in 3 risk of death? Shariat et al. Eur Urol 2007
20 Neoadjuvant chemotherapy delays surgery and leads to increased morbidity? SWOG 8710: Radical cystectomy performed in 82% MVAC arm vs. 81% control Median time to cystectomy in MVAC arm 115 days (11-169) MD Anderson: RCT of neoadjuvant vs. adjuvant chemotherapy in 140 pts w/ locally advanced bladder cancer No difference in failure to undergo cystectomy (3 vs. 5) No significant difference in OR time, EBL, transfusion rate No significant difference in complications Grossman et al. N Engl J Med 2003; Hall et al. Urology 1996
21 Neoadjuvant chemotherapy delays surgery and leads to increased morbidity? SWOG 8710: Radical cystectomy performed in 82% MVAC arm vs. 81% control Median time to cystectomy in MVAC arm 115 days (11-169) MD Anderson: RCT of neoadjuvant vs. adjuvant chemotherapy in 140 pts w/ locally advanced bladder cancer No difference in failure to undergo cystectomy (3 vs. 5) No significant difference in OR time, EBL, transfusion rate No significant difference in complications Grossman et al. N Engl J Med 2003; Hall et al. Urology 1996
22 Patients are just as likely to receive 3-4 cycles of chemotherapy if it is deferred to adjuvant setting? Neoadjuvant: SWOG 8710: 87% received MVAC arm received 1 cycle BA6 3094: 80% of CMV arm received 3+ cycles MD Anderson: RCT neoadjuvant vs. adjuvant chemo 97% (68 of 70) randomized to neoadjuvant arm received 2 cycles MVAC vs. 77% (54 of 70) in adjuvant arm 13% in adjuvant arm received no chemotherapy Adjuvant: 25% of pts in 2 of 4 trials received no chemotherapy Grossman et al. N Engl J Med 2003; Griffiths et al. J Clin Oncol 2011
23 Patients are just as likely to receive 3-4 cycles of chemotherapy if it is deferred to adjuvant setting? Neoadjuvant: SWOG 8710: 87% received MVAC arm received 1 cycle BA6 3094: 80% of CMV arm received 3+ cycles MD Anderson: RCT neoadjuvant vs. adjuvant chemo 97% (68 of 70) randomized to neoadjuvant arm received 2 cycles MVAC vs. 77% (54 of 70) in adjuvant arm 13% in adjuvant arm received no chemotherapy Adjuvant: 25% of pts in 2 of 4 trials received no chemotherapy Millikan et al. J Clin Oncol 2001
24 Patients are just as likely to receive 3-4 cycles of chemotherapy if it is deferred to adjuvant setting? Neoadjuvant: SWOG 8710: 87% received MVAC arm received 1 cycle BA6 3094: 80% of CMV arm received 3+ cycles MD Anderson: RCT neoadjuvant vs. adjuvant chemo 97% (68 of 70) randomized to neoadjuvant arm received 2 cycles MVAC vs. 77% (54 of 70) in adjuvant arm 13% in adjuvant arm received no chemotherapy Adjuvant: 25-38% of pts in 3 of 5 trials received no chemotherapy Advanced Bladder Cancer Meta-Analysis Collaboration et al. Eur Urol 2005
25 Are patients likely to receive 3-4 cycles of chemotherapy if it is deferred to adjuvant setting? MSKCC: 1142 pts, All complications within 90 days of surgery, modified Clavien system 64% (N=735) experienced a complication; 83% grade II-V 26% (N=298) required readmission 30% (N= 347) may not be eligible to receive postoperative chemotherapy due to important postoperative complications* * Defined as grade II-V complication occurring within 6-12 wks of surgery Donat et al. Eur Urol 2009
26 It s not just about giving chemotherapy before cystectomy!! Cleveland Clinic, of 117 (25%) RC patients received neoadjuvant chemotherapy pt0: 7% pt3-4 or pn+: 62% In SWOG % pt0 and 31% pt3-4 Chemotherapy: 14% MVAC, 69% GC, 17% other regimens Median time to cystectomy: 208 days (IQR: ) In SWOG days It s about appropriate chemotherapy and timely cystectomy! Weight et al. Cancer 2009
27 It s not just about giving chemotherapy before cystectomy!! Cleveland Clinic, of 117 (25%) RC patients received neoadjuvant chemotherapy pt0: 7% pt3-4 or pn+: 62% In SWOG % pt0 and 31% pt3-4 Chemotherapy: 14% MVAC, 69% GC, 17% other regimens Median time to cystectomy: 208 days (IQR: ) In SWOG days It s about appropriate chemotherapy and timely cystectomy! Weight et al. Cancer 2009
28 Neoadjuvant vs. Adjuvant Chemotherapy Cystectomy alone is insufficient for majority of patients with muscle-invasive bladder cancer Perioperative chemotherapy is associated with 5-14% improvement in survival at 5 years The best evidence is for neoadjuvant chemotherapy Patients are more likely to receive the optimal therapy is chemotherapy is administered before cystectomy Timely cystectomy is critical in this equation!!!
29
30
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
Lymph node dissection: how much is enough?
1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
Neodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
UROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic
Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
Invasive Bladder Transitional Cell Carcinoma OBJECTIVES
Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder
ROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life.
THE INTERNATIONAL CONFERENCE PROGRESS IN URO-ONCOLOGY 5th Edition September, 25th 26th 2014 CLUJ-NAPOCA Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life. Dr.
When to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London
Chemo-radiotherapy in muscle invasive bladder cancer Dr Paula Wells St Bartholomew s Hospital London Overview Evidence base for cystectomy vs bladder preservation Chemo-radiotherapy vs radiotherapy alone
Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
Case Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre
CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy
Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy
Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy Anirban P. Mitra, M.D., Ph.D. Center for Personalized Medicine University of Southern California
Urinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
Early radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
Detection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
Treatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
Intravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study
Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study Dr Alexandre Peltier Institut Jules Bordet, Bruxelles (BE) The 9 th Congress of the Lebanese Urology Society
Disclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI
BJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival
with metastatic breast and colorectal cancer who are treated with chemotherapy. In breast, lung and colorectal cancer, the value of early chemotherapy in operable localized and locally advanced disease
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent
Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Jehonathan H Pinthus MD, Ph.D, FRCSC Associate Professor Department of Surgery/Urology McMaster University Life expectancy Current age
Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
Ode to a node Lymph node dissec3on in prostate and bladder cancer
5/26/10 Ode to a node Lymph node dissec3on in prostate and bladder cancer Anthony Koupparis 1 Introduc3on prostate cancer PLND most accurate and reliable staging method for LNI Imaging techniques have
Patient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy
ORIGINAL ARTICLE Vol. 42 (4): 663-670, July - August, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0393 A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
Complications in robotic surgery!! Review of the literature! RALP, RAPN and RARC!
Complications in robotic surgery Review of the literature RALP, RAPN and RARC Anna Wallerstedt, MD Karolinska University Hospital Stockholm, Sweden Agenda The importance of reporting surgical complications
Advances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
Collection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
Neoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
Radical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
September 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
Neoadjuvant and Adjuvant Chemotherapy in Bladder Cancer
Neoadjuvant and Adjuvant Chemotherapy in Bladder Cancer Neal D. Shore, MD,FACS Carolina Urologic Research Center Myrtle Beach South Carolina IBCU, 2017 Alan Yagoda, MD New York Times :Obituary Dr. Alan
Debate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
M D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
Timing of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
Trimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
Lymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair
Old and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute
Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member
Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?
Bladder Cancer 2 (2016) 441 448 DOI 10.3233/BLC-160071 IOS Press Research Report 441 Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Thenappan
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
Locally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy
Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy Kimberley S. Mak, MD, MPH Assistant Professor Boston Medical Center Boston University
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
(Neo-) adjuvant Treatment of Gastric Cancer. - The European View
(Neo-) adjuvant Treatment of Gastric Cancer - The European View Florian Lordick, MD Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) University of Leipzig, Germany My Conflict
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients
EUROPEAN UROLOGY 61 (2012) 1039 1047 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant
Options for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer
Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized
Chemotherapy for Urological Cancers
Chemotherapy for Urologic Cancers Matthew Rettig, MD Associate Professor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director, Prostate Cancer Program Institute
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
Highlighting Clinical Trials Muscle Invasive Bladder Cancer
Highlighting Clinical Trials Muscle Invasive Bladder Cancer Part I: The Basics of MIBC Clinical Trials June 19, 2018 Presented by: Dr. Peter Black is a urologic oncologist at Vancouver General Hospital,
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
Outcomes. Glickman Urological & Kidney Institute
Outcomes 28 Glickman Urological & Kidney Institute Prostate Cryotherapy Cryotherapy has recently been used for treatment of prostate cancer as primary treatment and after failure of radiation treatment.
Adjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
Conclusions. Keywords
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,
3.1 Investigations for Patients Presenting with Haematuria Table 1
3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements
Controversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
Research Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
Advances in Urology Volume 14, Article ID 746298, 6 pages http://dx.doi.org/1.1155/14/746298 Research Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions N.
Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
Cochrane metaanalysis 5 year OS Intent to treat
RADICAL CYSTECTOMY IS THE ONLY EFFECTIVE TREATMENT FOR PATIENTS WITH OPERABLE MUSCLE INVASIVE BLADDER CANCER The Con position Scott Tyldesley Radiation Oncology, Vancouver Centre, BC Cancer Agency Cochrane
Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.
Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature William Julian, MD James J. Stark, MD, FACP Maryview Medical Center February 20, 2009 Dr. Julian to
Presentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013
Advances in Urology Volume 2013, Article ID 317190, 6 pages http://dx.doi.org/10.1155/2013/317190 Research Article Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin
Early Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
Melanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
Medicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
Treatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
Unresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days